All updated as on -
By 2030, the market for CRISPR gene editing is projected to reach USD 21,325 billion, growing at a CAGR of 30% from 2023 to 2030.
Over the past few years, the governments of various nations throughout the world have made large financial investments in genomics research, which has aided in the discovery and study of novel CRISPR genome editing technologies. Additionally, the availability of financial aid has enabled government organisations and university institutions to conduct a significant amount of research in the area of genome engineering.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is an easy-to-use and highly efficient nucleic acid-targeting editing tool for the genome. Thanks to this technique, researchers may easily alter DNA sequences and regulate gene activity. It has the potential to be applied in a number of situations, such as fixing genetic flaws, treating illnesses, and stopping the spread of diseases. This new technology (Transcription Activator-Like Effector Nucleases) is replacing older techniques for editing DNA, such as ZFNs (Zinc Finger Nucleases) and TALENs because it is more accurate, faster, and less expensive. In order to use the method for the routine treatment of human ailments, researchers are focusing on its application in animal models or human cells that have been separated from the body. An infectious disease has been linked to a newly identified virus known as COVID-19. Leading pharmaceutical and biotechnology firms as well as players in the CRISPR genome industry have started developing vaccines in response to the COVID-19 pandemic's widespread impact. Due to the increased demand for vaccinations and possible antiviral medications, genome editing techniques are currently in the lead. Expanding CRISPR gene editing research and development initiatives are predicted to be the main engine of market expansion over the next years. As an illustration, in 2018 CRISPR Therapeutics and Vertex began the first-ever clinical research using CRISPR genome editing technology. An investigational therapy for the blood disorder beta-thalassemia was put to the test in the Regensburg, Germany research.
The CRISPR Gene Editing Market is divided into several types, including Cell Line and Engineering, Screening Services, gRNA Design, Vector Construction, and Others. With the greatest market share of 32% and the highest market value of 643.5 billion in 2021, the cell line and engineering sector led the market. The cell line and engineering segment of the gene editing industry is particularly consolidated as a result of the broad application of gene-manipulation techniques in stem cell research. The productivity of CHO cell lines has grown thanks to the use of CRISPR technology, which has increased the usage of this technology in the production of biopharmaceuticals and consequently raised the revenue of this market segment.
Report Coverage
Global CRISPR Gene Editing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global CRISPR Gene Editing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and CRISPR Gene Editing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key CRISPR Gene Editing market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global CRISPR Gene Editing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, CRISPR Gene Editing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., Mammoth Biosciences, Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global CRISPR Gene Editing market based on the below-mentioned segments:
Global CRISPR Gene Editing Market, By Type
Global CRISPR Gene Editing market, By Application
Global CRISPR Gene Editing market, Regional Analysis
Over the past few years, the governments of various nations throughout the world have made large financial investments in genomics research, which has aided in the discovery and study of novel CRISPR genome editing technologies. Additionally, the availability of financial aid has enabled government organisations and university institutions to conduct a significant amount of research in the area of genome engineering.
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is an easy-to-use and highly efficient nucleic acid-targeting editing tool for the genome. Thanks to this technique, researchers may easily alter DNA sequences and regulate gene activity. It has the potential to be applied in a number of situations, such as fixing genetic flaws, treating illnesses, and stopping the spread of diseases. This new technology (Transcription Activator-Like Effector Nucleases) is replacing older techniques for editing DNA, such as ZFNs (Zinc Finger Nucleases) and TALENs because it is more accurate, faster, and less expensive. In order to use the method for the routine treatment of human ailments, researchers are focusing on its application in animal models or human cells that have been separated from the body. An infectious disease has been linked to a newly identified virus known as COVID-19. Leading pharmaceutical and biotechnology firms as well as players in the CRISPR genome industry have started developing vaccines in response to the COVID-19 pandemic's widespread impact. Due to the increased demand for vaccinations and possible antiviral medications, genome editing techniques are currently in the lead. Expanding CRISPR gene editing research and development initiatives are predicted to be the main engine of market expansion over the next years. As an illustration, in 2018 CRISPR Therapeutics and Vertex began the first-ever clinical research using CRISPR genome editing technology. An investigational therapy for the blood disorder beta-thalassemia was put to the test in the Regensburg, Germany research.
The CRISPR Gene Editing Market is divided into several types, including Cell Line and Engineering, Screening Services, gRNA Design, Vector Construction, and Others. With the greatest market share of 32% and the highest market value of 643.5 billion in 2021, the cell line and engineering sector led the market. The cell line and engineering segment of the gene editing industry is particularly consolidated as a result of the broad application of gene-manipulation techniques in stem cell research. The productivity of CHO cell lines has grown thanks to the use of CRISPR technology, which has increased the usage of this technology in the production of biopharmaceuticals and consequently raised the revenue of this market segment.
Report Coverage
Global CRISPR Gene Editing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global CRISPR Gene Editing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and CRISPR Gene Editing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key CRISPR Gene Editing market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., Mammoth Biosciences, Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of CRISPR Gene Editing Market from 2021 to 2030.
- Market Forecast for CRISPR Gene Editing Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, CRISPR Gene Editing competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on CRISPR Gene Editing
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global CRISPR Gene Editing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, CRISPR Gene Editing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., Mammoth Biosciences, Inc.
Primary Target Market
- Market Players of CRISPR Gene Editing
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global CRISPR Gene Editing market based on the below-mentioned segments:
Global CRISPR Gene Editing Market, By Type
- Cell Line and Engineering
- Screening Services
- gRNA design and Vector Construction
- Others
Global CRISPR Gene Editing market, By Application
- Biomedical
- Agriculture
- Industrial
- Others CRISPR
Global CRISPR Gene Editing market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive crispr gene editing market market research and competitor analysis for your business to help you develop more profound insights into the crispr gene editing market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the crispr gene editing market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.